(480) 821-2838


(QOPI) Certification program, an affiliate of the American Society of Clinical Oncology - Learn More

Open Trials

Breast Cancer Trials:

Previously treated metastatic HER2+Breast Cancer

Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer (SOPHIA)
New sub-study includes margetuximab plus chemotherapy with decreased infusion time.
https://clinicaltrials.gov/ct2/show/NCT02492711?term=CP-MGAH22-04&rank=1
For questions, please contact 480-398-7671.

 

Previously treated Hormone receptor-positive, HER2 negative metastatic breast cancer whose disease progressed after prior systemic therapy

Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer (SHERBOC)
https://clinicaltrials.gov/ct2/show/NCT02492711?term=CP-MGAH22-04&rank=1
For questions, please contact 480-398-7671.

 

Lung Cancer Trials:

2nd or 3rd line treatment for Non-Small Cell Lung Cancer (NSCLC) after prior Platinum-Based Chemotherapy

Assessment of Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC With at Least One Measurable Lung Lesion (DUBLIN-3)
https://clinicaltrials.gov/ct2/show/NCT02504489
For questions please contact 480-398-7671.

 

Previously treated small cell lung cancer (SCLC)

Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) Versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (ATLANTIS)
https://clinicaltrials.gov/ct2/show/NCT02566993?term=PM1183-C-003-14&rank=1

For questions, please contact 480-398-7671.

 

Lymphoma Trials:

Previously treated Non-Hodgkin’s Lymphoma (Follicular, Small Lymphocytic Leukemia, Marginal Zone, Diffuse Large B-Cell Lymphoma)

https://clinicaltrials.gov/ct2/show/NCT02793583?term=UTX-TGR-205&rank=1

For questions please contact 480-398-7671.

 

Melanoma Trials:

Maintenance Treatment for Patients with Resected Stage IIB, IIC, or III Melanoma

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence.
https://clinicaltrials.gov/ct2/show/NCT01546571?term=103A-301&rank=1
For questions, please contact 480-398-7671.
*ENROLLMENT IS CURRENTLY ON HOLD FOR THIS TRIAL**

 

Prostate Cancer Trials:

Metastatic castration-resistant prostate cancer with no prior treatment

Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer (IPATential150)
https://clinicaltrials.gov/ct2/show/NCT03072238?term=CO39303&rank=1
For questions please contact 480-398-7671.

 

Localized or locally advanced Prostate Cancer receiving radiation

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
https://clinicaltrials.gov/ct2/show/NCT02531516?term=56021927PCR3003&rank=1
For questions please contact 480-398-7671.